(Reuters) -Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

Interim CEO Jake Leach said the company’s performance was driven by continued expansion of access to the G7 system, which helps people with diabetes track their glucose levels without finger pricks.

During the quarter, Dexcom added coverage for G7 under Canada’s Ontario Drug Benefit Program, making it available to more people on insulin therapy.

The company also launched an AI-powered meal logging feature in both its G7 and Stelo apps, aimed at helping users better understand how food affects their glucose levels.

Stelo, Dexcom’s over-the-counter CGM for adults not on insulin, brought in over $100 million in re

See Full Page